Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Elevation Oncology, Inc. ELEV NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
41/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$9.00
+2365.8%

Elevation Oncology, Inc. (ELEV) is a Biotechnology company in the Healthcare sector, currently trading at $0.37. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Analyst consensus target is ELEV = $9 (+2365.8% upside).

Net income is $44M (loss), growing at -47.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $31M against $60M equity (Debt-to-Equity (D/E) ratio 0.52, moderate). Current ratio is 21.21 (strong liquidity). Debt-to-assets is 32.6%. Total assets: $96M.

Analyst outlook: 3 / 12 analysts rate ELEV as buy (25%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future 52/100 (Partial), Income ?/100 (Fail).

$9.00
▲ 2365.75% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Elevation Oncology, Inc., the average price target is $9.00, with a high forecast of $10.00, and a low forecast of $8.00.
Highest Price Target
$10.00
Average Price Target
$9.00
Lowest Price Target
$8.00

ELEV SharesGrow Score Overview

49/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ELEV

✓
VALUE Pass
100/100
ELEV trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $9, implying +2365.8% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ELEV: +0%/yr revenue is, -47.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet ELEV: Debt-to-Equity (D/E) ratio 0.52 (moderate), Current ratio is 21.21 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ELEV: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 3 / 12 analysts rate ELEV as buy (25%). Analyst consensus target is $9 (+2365.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.221-3.09
Volume4.82M
Avg Volume (30D)1.35M
Market Cap$21.63M
Beta (1Y)1.50
Share Statistics
EPS (TTM)-0.78
Shares Outstanding$57.28M
IPO Date2021-06-25
Employees34
CEOJoseph J. Ferra Jr.
Financial Highlights & Ratios
EBITDA$-44.7M
Net Income$-44.49M
Operating Income$-44.7M
Total Cash$93.18M
Total Debt$31.13M
Net Debt$-18.33M
Total Assets$95.63M
Price / Earnings (P/E)-0.5
Analyst Forecast
1Y Price Target$9.00
Target High$10.00
Target Low$8.00
Upside+2,365.8%
Rating ConsensusHold
Analysts Covering12
Buy 25% Hold 67% Sell 8%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS28623U1016

Price Chart

Track all markets on TradingView
ELEV
Elevation Oncology, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.22 52WK RANGE 3.09

People Also View

ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 AVRO
AVRO
AVROBIO, Inc.
$1.40
-1.41%
 CWBR
CWBR
CohBar, Inc.
$0.41
+0.00%
 ENVB
ENVB
Enveric Biosciences, Inc.
$1.95
-1.02%
 HEPA
HEPA
Hepion Pharmaceuticals, Inc.
$0.05
+18.52%
 OCEA
OCEA
Ocean Biomedical, Inc.
$0.00
+0.00%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message